IMPACT OF SEMAGLUTIDE ON GLYCEMIC CONTROL AND POST-PRANDIAL GLUCOSE REDUCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

• DOI: 10.22533/at.ed.1593462328062

• Palavras-chave: Semaglutide; Glycemic control; Postprandial blood glucose.

• Keywords: Semaglutide; Glycemic control; Postprandial blood glucose.

• Abstract:

  Objective: To evaluate the potential of semaglutide as an adjuvant therapy in glycemic control and in the reduction of postprandial glycemia in patients with type 2 Diabetes Mellitus. Methodology: This narrative bibliographic review, conducted from April to May 2023, was developed according to the PVO strategy, an acronym that represents: population or research problem, variables and outcome. The literature search was performed on the PubMed database. After applying the inclusion and exclusion criteria, 17 articles were selected, published between 2017 and 2022, to compose the collection of this study. Results: Semaglutide has proven benefits for diabetic patients due to its ability to significantly reduce postprandial blood glucose by delaying gastric emptying, enhancing insulin secretion and inhibiting the secretion of the hormone glucagon. Final considerations: Despite being a recent drug, the literature converges to the consolidation of semaglutide as a promising medication in postprandial glycemic control in patients with type 2 Diabetes Mellitus, contributing to a better prognosis of the disease.